You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Trastuzumab Deruxtecan

Showing 1 - 25 of 1,038
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Stomach Tumor Trial (Trastuzumab deruxtecan, Afatinib)

Not yet recruiting
  • Stomach Neoplasm
  • (no location specified)
Oct 16, 2023

Brain Cancer, Glioblastoma, Metastatic Cancer Trial in New York (Trastuzumab deruxtecan)

Recruiting
  • Brain Cancer
  • +4 more
  • Trastuzumab deruxtecan
  • New York, New York
    Memorial Sloan Kettering Cancer Center (All Protocol Activities)
Sep 22, 2023

Breast Cancer Trial (Trastuzumab Deruxtecan)

Not yet recruiting
  • Breast Cancer
  • Trastuzumab Deruxtecan
  • (no location specified)
Jul 10, 2023

HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma Trial (Trastuzumab deruxtecan)

Not yet recruiting
  • HER2-positive Advanced Gastric Cancer
  • HER2-positive Gastroesophageal Junction Adenocarcinoma
  • Trastuzumab deruxtecan
  • (no location specified)
Aug 11, 2023

Breast Cancer Trial in Sweden (Trastuzumab deruxtecan, Docetaxel, Paclitaxel)

Not yet recruiting
  • Breast Cancer
  • Trastuzumab deruxtecan
  • +9 more
  • Malmö, Sweden
  • +6 more
Jun 8, 2023

HER2-positive Breast Cancer Trial in Amsterdam (Trastuzumab deruxtecan)

Not yet recruiting
  • HER2-positive Breast Cancer
  • Trastuzumab deruxtecan
  • Amsterdam, Netherlands
    Antoni van Leeuwenhoek
Aug 7, 2023

Breast Cancer, Metastatic Breast Cancer Trial (Trastuzumab-Deruxtecan (T-DXd))

Not yet recruiting
  • Breast Cancer
  • Metastatic Breast Cancer
  • Trastuzumab-Deruxtecan (T-DXd)
  • (no location specified)
Sep 20, 2023

Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial in New Haven (procedure, drug, biological)

Recruiting
  • Metastatic Malignant Solid Neoplasm
  • Unresectable Malignant Solid Neoplasm
  • Biopsy
  • +2 more
  • Boston, Massachusetts
  • +2 more
Jan 25, 2023

Breast Cancer Trial in Houston (Trastuzumab deruxtecan, Valemetostat)

Not yet recruiting
  • Breast Cancer
  • Houston, Texas
    M D Anderson Cancer Center
Dec 14, 2022

DESTINY Breast Respond HER2-low Europe

Not yet recruiting
  • Unresectable Breast Cancer
  • +2 more
  • Trastuzumab deruxtecan
  • (no location specified)
Jul 6, 2023

HER2-positive Breast Cancer Trial in Ireland (trastuzumab deruxtecan (T-DXd) (IV))

Not yet recruiting
  • HER2-positive Breast Cancer
  • trastuzumab deruxtecan (T-DXd) (IV)
  • Galway, Connaught, Ireland
  • +4 more
Jan 24, 2023

Metastatic Breast Cancer Trial in Rome (HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and

Recruiting
  • Metastatic Breast Cancer
  • HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment
  • Rome, Italy
    Fondazione Policlinico A. Gemelli - IRCCS
Jun 22, 2023

Triple-Negative Breast Cancer Trial in Shanghai (Trastuzumab Deruxtecan)

Not yet recruiting
  • Triple-Negative Breast Cancer
  • Trastuzumab Deruxtecan
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Jul 12, 2023

Invasive Breast Cancer, Inflammatory Breast Cancer Stage III, HER2-positive Breast Cancer Trial in Boston (Trastuzumab

Not yet recruiting
  • Invasive Breast Cancer
  • +4 more
  • Boston, Massachusetts
  • +1 more
Mar 20, 2023

HER2-positive Early Breast Cancer Trial in Germany (Trastuzumab deruxtecan, Standard-of-Care)

Not yet recruiting
  • HER2-positive Early Breast Cancer
  • Munich, Bavaria, Germany
  • +11 more
Jan 19, 2023

Gastric Cancer Trial in Philadelphia (Neratinib Pill, Fam-Trastuzumab Deruxtecan-Nxki (TDxD))

Suspended
  • Gastric Cancer
  • Neratinib Pill
  • Fam-Trastuzumab Deruxtecan-Nxki (TDxD)
  • Philadelphia, Pennsylvania
    Fox Chase Cancer Center
Jul 6, 2022

Esophageal Adenocarcinoma, Esophageal Cancer, HER-2 Protein Overexpression Trial in New York, Providence (Nivolumab, Trastuzumab

Not yet recruiting
  • Esophageal Adenocarcinoma
  • +3 more
  • New York, New York
  • +1 more
Jul 28, 2022

PROVIDENCE - Real-world Study in HER2-positive Unresectable or

Not yet recruiting
  • Breast Neoplasms
  • +2 more
    • (no location specified)
    Oct 7, 2022

    T-Dxd in Chinese Metastatic HER2-positive Breast Cancer Patients

    Active, not recruiting
    • Breast Cancer
    • Trastuzumab Deruxtecan
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Oct 25, 2022

    Breast Cancer Stage IV Trial in Vienna (Trastuzumab deruxtecan)

    Active, not recruiting
    • Breast Cancer Stage IV
    • Trastuzumab deruxtecan
    • Vienna, Austria
      AKH Universitaetsklinikum Vienna, Department f. Internal medicin
    Jul 26, 2022

    Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Cancer Trial in United States (drug,

    Recruiting
    • Early-stage Breast Cancer
    • +6 more
    • Fullerton, California
    • +8 more
    Sep 19, 2022

    Locally Advanced Breast Cancer, Metastatic Breast Cancer Trial in Spain (Trastuzumab deruxtecan)

    Not yet recruiting
    • Locally Advanced Breast Cancer
    • Metastatic Breast Cancer
    • Trastuzumab deruxtecan
    • Cádiz, Andalucía, Spain
    • +18 more
    Feb 24, 2023

    Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Tumor in the Brain Trial in Duarte

    Recruiting
    • Anatomic Stage IV Breast Cancer AJCC v8
    • +2 more
    • Copper Cu 64-DOTA-Trastuzumab
    • +4 more
    • Duarte, California
      City of Hope Medical Center
    Nov 22, 2022

    Previously Treated Advanced/Metastatic HER2-positive Breast

    Recruiting
    • HER2-positive Breast Cancer
    • Trastuzumab deruxtecan
    • Naples, Italy
    • +17 more
    Jan 31, 2023

    Metastatic Breast Cancer Trial (BDC-1001, Pertuzumab)

    Not yet recruiting
    • Metastatic Breast Cancer
    • (no location specified)
    Jul 12, 2023